2025 Outlook: Healthcare Technology & Innovation

M&A activity was a dominant theme, signaling continued consolidation within the healthcare sector. Several significant deals were announced or finalized around the conference. Among the most notable was Johnson & Johnson’s $14.6 billion acquisition of Intra-Cellular Therapies. That represents the largest biotech M&A transaction since late 2023. Further demonstrating the industry’s focus on targeted therapies, Eli Lilly acquired Scorpion Therapeutics for up to $2.5 billion. GSK bolstered its oncology portfolio with the $1 billion acquisition of IDRx.

The conference highlighted other key trends. Health Catalyst’s acquisition of Upfront Healthcare for $86 million underscored the increasing importance of patient engagement platforms. Stryker continued its diversification strategy with the acquisition of Inari Medical for $4.9 billion. Inari is a developer of devices for venous disease treatment. Roche also strategically expanded its pipeline, acquiring Poseida Therapeutics for $1.5 billion. That beefs up its pipeline in anticipation of the upcoming patent cliff for Keytruda in 2028. Radiopharmaceuticals emerged as a particularly hot area, building on the multibillion-dollar deals seen in 2024. This promising segment is projected to experience substantial growth, reaching an estimated $26.5 billion by 2031. That represents a 19% annual growth rate.

Beyond the M&A headlines, JPM25 highlighted several key trends poised to shape the healthcare landscape in the coming year. From the transformative potential of AI to the rapid advancements in liquid biopsy, the sector is brimming with innovation. Other key themes include the continued rise of robotic surgery, a complex U.S. policy environment, and strong financial projections

Artificial intelligence was a dominant theme at the conference. Companies are increasingly leveraging its power to transform healthcare. The focus is on enhancing R&D productivity, lowering operating costs, and improving efficiency across various domains. Diagnostics, drug discovery, and process automation are particularly ripe for AI-driven disruption. For example, AI is being used to analyze medical images for more accurate and faster diagnoses, accelerate the identification of drug candidates through sophisticated simulations, and automate administrative tasks to free up healthcare professionals’ time.

The decreasing cost of AI development, as demonstrated by DeepSeek’s recent announcement, has the potential to be a game-changer for healthcare. The availability of more affordable AI technologies could significantly accelerate its deployment across the sector. This increased accessibility could empower smaller companies, research institutions, and even individual healthcare providers to leverage AI’s capabilities. This would foster innovation and expand the range of AI-driven solutions in the field. This democratization of AI could lead to faster development cycles, more diverse applications, and ultimately, a greater impact on patient care.

Tempus, a leader in AI-driven precision medicine, showcased the transformative potential of AI in cancer care.  The launch of its FDA-approved xT CDx test, along with upgrades to its AI assistant, Tempus One, and the introduction of its AI-powered personal health concierge app, Olivia, represent significant strides in personalized cancer diagnostics and treatment. These advancements could lead to more targeted therapies, improved patient outcomes, and a more personalized healthcare experience.

Liquid biopsy technology is progressing at an accelerated pace. The prospect of broader insurance coverage for blood-based cancer diagnostics is on the horizon. This potential shift in reimbursement policy is being driven by growing evidence of the clinical utility and cost-effectiveness of liquid biopsies. It’s also being driven by increasing advocacy from patient groups and healthcare providers. This breakthrough has the potential to revolutionize cancer detection and monitoring. It would enable earlier diagnosis, more personalized treatment strategies, and less invasive procedures for patients.

While Guardant Health has achieved a significant milestone with its FDA-approved liquid biopsy test, the field is highly competitive and dynamic. Companies like Natera, Grail, Veracyte, and Exact Sciences are also making significant advances in developing highly sensitive and specific assays for various cancer types. This healthy competition is fueling rapid innovation in the field. That’s driving improvements in accuracy, expanding the range of detectable cancers. This will ultimately benefit patients through earlier detection and more targeted therapies.

The adoption of robots in operating rooms continues its upward trajectory. This is driven by well-established efficacy and increasingly innovative financing models making the technology more accessible to hospitals. This trend is expected to persist as robotic surgery platforms become even more sophisticated, expanding their capabilities across a wider range of surgical procedures. For example, advancements in areas like haptic feedback, improved dexterity, and enhanced imaging are enabling surgeons to perform increasingly complex minimally invasive surgeries with greater precision. This results in less tissue damage, reduced risk of infection, and potentially faster patient recovery.

This January saw the announcement from Koh Young Technology that it has received FDA clearance for its Geniant neurosurgical robot. Its ability to penetrate a U.S. market dominated by established players like HTEC members Stryker and Intuitive Surgical remains to be seen. Its strategy of initially targeting neurosurgery, before likely expanding into the larger and more competitive spine market, appears to be a wise and strategic move.

Going forward, as robotic surgery continues to evolve, it promises to transform the operating room. This offers the potential of improved patient outcomes, shorter recovery times, and greater surgical precision.

The new U.S. administration is creating uncertainty for vaccine manufacturers, while proposed reductions in regulatory hurdles could stimulate discovery and investment. The threat of tariffs is likely to accelerate onshoring efforts.

The U.S. healthcare landscape is navigating a complex and evolving policy environment. Uncertainty surrounds vaccine manufacturers. This is particularly so regarding future vaccine mandates and procurement strategies. Conversely, proposed reductions in regulatory hurdles for drug approvals and clinical trials could potentially stimulate discovery. It could also potentially stimulate investment in the pharmaceutical and biotech sectors. The ongoing threat of tariffs on medical devices and pharmaceuticals is also likely to accelerate existing trends toward onshoring and diversification of supply chains.

The recent confirmation of Robert F. Kennedy Jr. as the U.S. Secretary of Health and Human Services is no doubt likely to bring volatility from investors trying to figure out how much of his previous opinions will filter down into policy.

Regarding current projections for HTEC, index companies are expected to experience robust growth, with median sales projected at 8.33%, EBITDA at 11.67%, and EPS at 9.94%. This positive outlook reflects the overall health of the healthcare sector and the potential for continued innovation and growth.

AI is transforming healthcare, offering the potential to revolutionize diagnostics, drug discovery, and patient care.  Decreasing development costs are democratizing AI. This is making its power accessible to a wider range of companies and fostering rapid innovation. Liquid biopsy is another area of significant progress, promising earlier cancer detection and personalized treatment. The competitive landscape is driving advancements that will ultimately benefit patients.

Robotic surgery continues its expansion, with technological improvements and innovative financing models increasing accessibility. New entrants and established players are pushing the boundaries of what’s possible in the operating room. The U.S. policy environment presents some uncertainties. But the overall financial outlook for the healthcare sector remains strong.

Projected growth for HTEC companies indicates a healthy and expanding market. The convergence of technological innovation, increasing patient needs, and a generally positive financial outlook creates a favorable environment for investors. HTEC offers exposure to the most dynamic and promising areas of healthcare. This index is positioning investors to be able to capitalize on the industry’s long-term growth potential.

VettaFi LLC (“VettaFi”) is the index provider for the ROBO Global Healthcare Technology and Innovation Index HTEC, for which it receives an index licensing fee. However, HTEC is not issued, sponsored, endorsed or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of HTEC.

For more news, information, and analysis, visit our Disruptive Technology Channel.